These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 39030807)

  • 41. Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
    Muriel C; Esteban E; Corral N; Fonseca PJ; Luque M; Berros JP; Fernández Y; Blay P; Fra J; Villanueva N; Sanmamed M; Pardo P; Izquierdo M; Vieitez JM; Estrada E; Lacave ÁJ
    Clin Transl Oncol; 2010 Aug; 12(8):562-7. PubMed ID: 20709657
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Superior efficacy of immunotherapy-based combinations over monotherapy for EGFR-mutant non-small cell lung cancer acquired resistance to EGFR-TKIs.
    Yang L; Hao X; Hu X; Wang Z; Yang K; Mi Y; Yang Y; Xu H; Yang G; Wang Y
    Thorac Cancer; 2020 Dec; 11(12):3501-3509. PubMed ID: 33075201
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations.
    Wang F; Diao XY; Zhang X; Shao Q; Feng YF; An X; Wang HY
    Cancer Commun (Lond); 2019 Mar; 39(1):7. PubMed ID: 30823937
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors.
    Cao J; Zhang J; Peng W; Chen Z; Fan S; Su W; Li K; Li J
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):259-69. PubMed ID: 27299749
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A multi-center effectiveness comparison study of fruquintinib with constructed external control cohort of other targeted kinase inhibitors using real-world data in third-line treatment of metastatic colorectal cancer.
    Jin Y; Li J; Shen L; Xu J; Zhang Y; Zhang J; Pan H; Qu X; Chen Y; Zhang Q; Li J; Sun M; Qin S
    Front Oncol; 2022; 12():1044328. PubMed ID: 36505849
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: protocol for an open-label, non-randomised, Phase 2 study.
    Hara H; Kawamoto T; Fukase N; Kawakami Y; Takemori T; Fujiwara S; Kitayama K; Nishida K; Kuroda R; Akisue T
    BMC Cancer; 2019 Jul; 19(1):725. PubMed ID: 31337342
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Comparison of the efficacy of second line EGFR TKIs followed by third line pemetrexed or the reverse sequence in the treatment of advanced lung adenocarcinoma].
    Zhang RX; Cai DY; Hong TT; Wu XH; Hua D
    Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):147-51. PubMed ID: 22780936
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Analysis of bone and soft-tissue sarcomas registered during the year 2012 at Tata Memorial Hospital, Mumbai, with clinical outcomes.
    Bajpai J; Khanna N; Vora T; Gulia A; Laskar S; Puri A; Sanduptla B; Chinnaswamy G; Nayak P; Juvekar SL; Janu A; Desai S; Ghosh J; Purandare N; Ramadwar M; Rangarajan V; Rekhi B
    Indian J Cancer; 2018; 55(1):37-44. PubMed ID: 30147091
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of apatinib in advanced sarcoma: an open-label, nonrandomized, single-center study of 45 patients.
    Weitao Y; Fangxing W; Qiqing C; Jiaqiang W
    Anticancer Drugs; 2019 Aug; 30(7):e0778. PubMed ID: 31305297
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real-world efficacy, safety data and predictive clinical parameters for treatment outcomes in advanced soft tissue sarcoma treated with combined immunotherapy and antiangiogenic therapy.
    Li S; Sun Q; Bai R; Wang Y; Wang H; Chen H; Dong Y
    BMC Cancer; 2024 Aug; 24(1):1028. PubMed ID: 39164643
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial.
    Italiano A; Mir O; Mathoulin-Pelissier S; Penel N; Piperno-Neumann S; Bompas E; Chevreau C; Duffaud F; Entz-Werlé N; Saada E; Ray-Coquard I; Lervat C; Gaspar N; Marec-Berard P; Pacquement H; Wright J; Toulmonde M; Bessede A; Crombe A; Kind M; Bellera C; Blay JY
    Lancet Oncol; 2020 Mar; 21(3):446-455. PubMed ID: 32078813
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and efficacy of pazopanib as a second-line treatment and beyond for soft tissue sarcomas: A real-life tertiary-center experience in the MENA region.
    Halim NA; Sayed RE; Alameh IA; Khoury J; Nakib CE; Zerdan MB; Charafeddine M; Farhat F; Karak FE; Assi HI
    Cancer Treat Res Commun; 2021; 26():100275. PubMed ID: 33340905
    [TBL] [Abstract][Full Text] [Related]  

  • 53. European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy.
    Touati N; Schöffski P; Litière S; Judson I; Sleijfer S; van der Graaf WT; Italiano A; Isambert N; Gil T; Blay JY; Stark D; Brodowicz T; Marréaud S; Gronchi A
    Clin Oncol (R Coll Radiol); 2018 Jul; 30(7):448-454. PubMed ID: 29550245
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Efficacy and safety of Anlotinib in the treatment of advanced sarcoma].
    Yan Q; Yao WT; Du XH; Guo LY; Fan YC
    Zhonghua Zhong Liu Za Zhi; 2023 Oct; 45(10):904-910. PubMed ID: 37875427
    [No Abstract]   [Full Text] [Related]  

  • 55. Efficacy and safety of trabectedin for patients with unresectable and relapsed soft-tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study.
    Kobayashi H; Iwata S; Wakamatsu T; Hayakawa K; Yonemoto T; Wasa J; Oka H; Ueda T; Tanaka S
    Cancer; 2020 Mar; 126(6):1253-1263. PubMed ID: 31825533
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis.
    Takahashi M; Komine K; Imai H; Okada Y; Saijo K; Takahashi M; Shirota H; Ohori H; Takahashi S; Chiba N; Mori T; Shimodaira H; Ishioka C
    PLoS One; 2017; 12(5):e0176972. PubMed ID: 28489919
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase II trial of cetuximab in patients with metastatic or locally advanced soft tissue or bone sarcoma.
    Ha HT; Griffith KA; Zalupski MM; Schuetze SM; Thomas DG; Lucas DR; Baker LH; Chugh R
    Am J Clin Oncol; 2013 Feb; 36(1):77-82. PubMed ID: 22237145
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Is High-dose Radiation Therapy Associated With Early Revision Due to Aseptic Loosening in Patients With a Sarcoma of the Lower Extremities Reconstructed With a Cemented Endoprosthesis?
    Arnold MT; Geiger EJ; Hart C; Greig D; Trikha R; Sekimura T; Eckardt JJ; Bernthal NM
    Clin Orthop Relat Res; 2023 Mar; 481(3):475-487. PubMed ID: 35977001
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
    Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
    Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy.
    Liao Z; Li T; Zhang C; Liu X; Xing R; Teng S; Yang Y; Zhao G; Bai X; Zhao J; Yang J
    Cancer Biol Med; 2020 May; 17(2):501-512. PubMed ID: 32587785
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.